Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activat...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of experimental & clinical cancer research Vol. 38; no. 1; pp. 255 - 12
Main Author:	Rotte, Anand
Format:	Journal Article
Language:	English
Published:	London BioMed Central 13.06.2019 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Advances in Cancer Immunotherapy Amino acids Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Biomedical and Life Sciences Biomedicine Breast cancer Cancer Cancer Research Cancer therapies Care and treatment Cervical cancer Chemotherapy Clinical Trials as Topic Colorectal cancer Combination therapy CTLA-4 CTLA-4 Antigen - antagonists & inhibitors Gastric cancer Genetic aspects Humans Immunology Immunotherapy Kidney cancer Ligands Liver cancer Lung cancer Lymphocytes Lymphoma Medical research Melanoma Mesothelioma Metastasis Molecular Targeted Therapy Monoclonal antibodies Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Oncology PD-1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Review Studies T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Targeted cancer therapy Treatment Outcome Tumors CTLA-4 Combination therapy PD-1 Immunotherapy
ISSN:	1756-9966, 0392-9078, 1756-9966
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!